ONO-4059 hydrochloride

• CAT Number: I001695
• CAS Number: 1439901-97-9
• Molecular Formula: C25H23ClN6O3
• Molecular Weight: 490.94
• Purity: ≥95%
• Target: target:BTK.
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 6-amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one;hydrochloride
• InChI: InChI=1S/C25H22N6O3.ClH/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19;/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28);1H/t18-;/m1./s1
• InChIKey: UQYDCIJFACDXSG-GMUIIQOCSA-N
• SMILES: CC#CC(=O)N1CC[C@H](C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N.Cl

ONO-4059 hydrochloride（Cat No.:I001695）is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling. By inhibiting BTK, ONO-4059 blocks the activation and proliferation of B-cells, making it a valuable compound for research on B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma. Its specificity for BTK also makes it a potential therapeutic agent in autoimmune diseases like rheumatoid arthritis. ONO-4059 is crucial for exploring targeted therapies in cancer and immune-mediated disorders.

Reference

[1]. Harriet S et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 2016, 127:411-419

[2]. Akintunde Akinleye et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol, 2013, 6: 59.